Innovative therapeutics that matter
Discover Cellestia's innovative approach to address unmet medical
need in cancer treatment

Latest news

EHA Meeting

May 2016

Cellestia Biotech team will present a poster on CB-103 at the EHA Meeting 2016 (June 9-12).

Research

May 2016

Cellestia Biotech and Val D'Hebron Hospital of Oncology in Barcelona entered into research collaboration to support the development of the pan-NOTCH inhibitor CB-103.

Collaboration

April 2016

Cellestia Biotech and the Swiss Institute for Bioinformatics (SIB) have entered into a collaboration agreement.

About Cellestia biotech AG

Cellestia Biotech is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway.

Our unique mode of action
A Startup with more than 15 years of research in oncology

Cellestia’s pipeline is supported by more than 15 years of research in the field of oncology and cancer stem cells biology conducted under the supervision of Prof. Freddy Radtke.

Cellestia Biotech AG was founded in 2014 as a spin-off from
 Ecole Polytechnique Fédérale de Lausanne, EPFL and is managed by a high-calibre team of academic and industry professionals.


Vision of Cellestia

Cellestia is actively engaged in the development of first-in-class mechanisms-based targeted therapeutics to address unmet medical needs, with an emphasis on oncology and immunological disorders.

Our anti-cancer CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.


DISCOVER THE TEAM

The company is managed by a senior management team with a proven track record in cancer biology discovery and research, and drug development, business development and regulatory affairs.

In addition, an experienced team of industry and academic (university hospitals) consultants supports Cellestia’s drug development programs.

Cellestia Biotech's management team reflects a striking balance of academic excellence, extensive expertise in oncology drug development and global regulatory affairs.

  • Management team
    DR. MICHAEL BAUER

    CHIEF EXECUTIVE OFFICER
    BOARD MEMBER

    Biography
    DR. RAJWINDER LEHAL

    CHIEF SCIENTIFIC OFFICER

    BOARD MEMBER

    Biography
    Dr. Dirk Weber

    CHIEF MEDICAL OFFICER


    Biography
    Dr. Richard Peck

    Global Regulatory Affairs Manager

    Biography
  • Board of directors
    PROF. FREDDY RADTKE

    Chairman of the BoD
    Key Opinion Leader (KOL)

    Biography
    DR. MICHAEL BAUER

    CHIEF EXECUTIVE OFFICER

    
BOARD MEMBER

    Biography
    DR. RAJWINDER LEHAL

    CHIEF SCIENTIFIC OFFICER

    BOARD MEMBER

    Biography
  • Business advisory board
    Urs Breitenstein
    More
    Roger Meier
    More
    Dr. Maximilien Murone
    Biography
  • Scientific advisory board
    Dr. Doriano Fabbro

    CHAIRMAN OF THE SCIENTIFIC ADVISORY
 BOARD

    More
    Prof. Chantal Csajka

    SCIENTIFIC ADVISORY
 BOARD MEMBER

    More
    Dr. Robert A. Ettlin

    SCIENTIFIC ADVISORY
 BOARD MEMBER

    More
    Dr. Marc Lang

    SCIENTIFIC ADVISORY
 BOARD MEMBER

    More
    Dr. Maximilien Murone

    SCIENTIFIC ADVISORY
 BOARD MEMBER

    Biography
  • Oncology advisory board
    Dr. Francesc Bosch Albareda

    ONCOLOGY ADVISORY
BOARD MEMBER

    More
    Dr. Javier Cortes

    ONCOLOGY ADVISORY
 BOARD MEMBER

    More
    Dr. Richard Herrmann

    ONCOLOGY ADVISORY
 BOARD MEMBER

    More
    Dr. Paolo Nuciforo

    ONCOLOGY ADVISORY
 BOARD MEMBER

    More
    Dr. Josep Tabernero

    ONCOLOGY ADVISORY
 BOARD MEMBER

    More

Cellestia's pipeline

An innovative approach to address unmet medical need
in cancer treatment !

Lead development compound CB-103 is a first-in-class, oral pan-NOTCH inhibitor; it has been selected as Development Candidate to initiate preclinical development as targeted oncology therapy. To allow a personalized medicine approach, development of CB-103 will be complemented with a companion diagnostic to allow selection of the appropriate patients with NOTCH dependent disease.

CB-103
Oral Pan-NOTCH inhibitor

Discovery
Preclinical
Phase 1
Phase 2

Understand how it works

CB-103 Inhibits cancerous cells by blocking the notch pathway

THIS IS A HEALTHY CELL

It can be cell from breast, lung, blood, or any other tissue of the body that can become cancerous


1CELL
2NUCLEUS
CARCINOGENS DAMAGING A HEALTHY CELL

In a lifetime, humans are exposed to DNA damage causing agents known as carcinogens


3CARCINOGENS
ALTERATION OF THE DNA

As a result of carcinogens exposure and DNA damage, certain cells acquire elevated level of Notch proteins and/or mutations in Notch proteins


4ELEVATED NOTCH PROTEIN
ACTIVATION OF THE NOTCH PATHWAY

The activation of Notch receptors results in Notch intracellular domain translocation into the nucleus, and activation of oncogenic programs


5NOTCH INTRACELLULAR DOMAIN
TRANSFORMATION INTO CANCEROUS CELL

Once the Notch pathway is on, oncogenic programs transform healthy cells into cancerous cells


6ONCOGENIC PROGRAMS
CB-103 INHIBITS THE NOTCH PATHWAY

By directly targetting Notch in the nucleus, CB-103 is shutting down oncogenic programs


7CB-103
OUTCOME OF CB-103 TREATMENT

As a result of the treatment, Notch driven cancerous cells are eliminated

  • 1CELL

  • 2NUCLEUS

  • 3NOTCH RECEPTORS

  • 4NOTCH LIGANDS

  • 5NOTCH INTRACELLULAR DOMAIN

  • 6ONCOGENIC PROGRAMS

  • 7CB-103

Step 5 - Conductive glass

INVESTORS

Cellestia Biotech AG is a privately held company.

Cellestia Biotech AG is in a unique position to capitalize on several factors to establish itself as a successful drug development company. An established track record of its founders and strategic advisors in cancer drug development and world-renowned expertise in Notch signaling provides depth to its expertise.


Cellestia’s ability to exploit Notch transcriptional activation complex modulation (both inhibitors and activators programs) provides a key competitive advantage over its competitors.

Financing for the initial research period has been secured in seed funding in May 2014 from private investors and, later from the Swiss Innovation Promotion Agency KTI/CTI. In addition, Cellestia Biotech AG is enjoying unique support by EPFL, in terms of the use of laboratories and support and the Technology Park Basel, where the Development Office is based.


To find out more about investment opportunities with Cellestia Biotech AG, contact us: [email protected]


Contact us

BASEL

Technology Park Basel
Hochbergerstrasse 60C
CH-4057 Basel

LAUSANNE

Innovation Park EPFL
Building C
CH-1015 Lausanne